CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-29 | Manning Anthony M. Director | Option exercise · Stock Option (Right to Buy) | −10,000 | 2,100 | ||
| 2026-06-24 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +30,000 | $7.56 | $227K | 89,992 |
| 2026-06-24 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −30,000 | $21.42 | $643K | 59,992 |
| 2026-06-24 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 66,000 | ||
| 2026-06-23 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $7.56 | $45K | 71,837 |
| 2026-06-23 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −11,845 | $20.22 | $240K | 59,992 |
| 2026-06-23 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 96,000 | ||
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Option exercise 10b5-1 | +3,000 | $6.14 | $18K | 70,845 |
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −3,000 | $20.00 | $60K | 67,845 |
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 203,290 | ||
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Option exercise 10b5-1 | +2,175 | $3.98 | $9K | 64,546 |
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,175 | $20.00 | $44K | 62,371 |
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,175 | 31,298 | ||
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Option exercise 10b5-1 | +2,176 | $3.98 | $9K | 64,547 |
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,176 | $19.00 | $41K | 62,371 |
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,176 | 33,473 | ||
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Option exercise 10b5-1 | +3,000 | $6.14 | $18K | 70,845 |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −3,000 | $19.00 | $57K | 67,845 |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 206,290 | ||
| 2026-06-11 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +25,800 | 25,800 |
Page 2 of 9 · 174 trades